ALX ONCOLOGY HOLDINGS INC (ALXO) Form 8-K — Aug 6, 2026

$ALXOForm 8-KItems 2.02, 9.01Filed Aug 6, 2026, 8:05 AM ET0001193125-26-336843Original filing

ALX Oncology reported a narrower GAAP net loss of $18.0 million for the second quarter of 2026, compared to a loss of $25.9 million in the prior year period. The company also reported a net loss per share of $(0.13) for the quarter, a significant improvement from $(0.49) in the prior year. The company's cash, cash equivalents, and investments totaled $153.4 million as of June 30, 2026, which management believes is sufficient to fund planned operations through the first half of 2028. The company also announced the appointment of Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel, and refinanced its debt with HSBC Ventures USA Inc.

Key figures

Eps: -0.13
Eps Beat: 0
Revenue: 0
Net Income: -18.0
Total Debt: 0
Revenue Yoy: 0
Total Assets: 160.6
Cash Position: 153.4
Shares Outstanding: 135.6

Price after filing

1 day: -2.5%7 days: -1.5%30 days: +2.0%

Close on the filing date to close N calendar days later (from $1.97). Historical, not a forecast.

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.